Trinity Biotech plc (NASDAQ:TRIB)’s share price rose 6.3% during trading on Wednesday . The company traded as high as $12.97 and last traded at $12.78, with a volume of 95,495 shares traded. The stock had previously closed at $12.02.

Separately, Zacks Investment Research upgraded Trinity Biotech plc from a “sell” rating to a “hold” rating in a report on Saturday. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $17.00.

The stock has a market cap of $292.53 million and a P/E ratio of 54.09. The company has a 50-day moving average price of $12.03 and a 200-day moving average price of $11.27.

Trinity Biotech plc (NASDAQ:TRIB) last issued its quarterly earnings results on Thursday, July 21st. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.03. The firm had revenue of $26.30 million for the quarter, compared to analyst estimates of $24.30 million. Analysts anticipate that Trinity Biotech plc will post $0.14 earnings per share for the current year.

A hedge fund recently bought a new stake in Trinity Biotech plc stock. Bank of Montreal Can bought a new position in Trinity Biotech plc (NASDAQ:TRIB) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 1,109,258 shares of the company’s stock, valued at approximately $13,045,000. Bank of Montreal Can owned 4.78% of Trinity Biotech plc as of its most recent filing with the SEC.

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.